• Company Profile
    Hebei Tuolu Supply Chain Management Co. Ltd is a famous Chinese used machine trading company. It is located in Tangshan City, Hebei Province, China. We specialized in supplying used construction machinery, mainly excavators, wheel loaders and related parts. The company has many famous brands of second-hand excavators such as Caterpillar, Doosan, Hitachi, Kato, Hyundai, XCMG, Sany etc.
    Our company has two parking places with more than 1000 sets of excavators with different models and brands. After more than 30 years of development, our company developed from construction sites to a leading group which to do both construction works and trading for used construction machinery. With the core value of "Customer First", we try to build long term business relationship with each customer.
    Our Advantages are as follows:
    1. More than 30 years history of used construction machinery trading;
    2. Famous project contractor in Northern China;
    3. Big procurement amount which can ensures variety of excavators;
    4. Low price with good condition of excavators.
    5. We can find the right vehicle according to buyer's request.
    Hebei Tuolu Supply Chain Management Co., Ltd welcomes all in China and oversea friends to build serious and long term business relationships.
    Our History:
    We are in this field for more than 30 years. At first, we just did construction works. Then we fond the great opportunity of used construction machinery, we began to cooperate with Chinese famous brands. Now we cooperate with many world famous brands and our products is not only well sold in domestic market, but also exported to Southeast Asia, such as Malaysia etc.Used Caterpillar 966H Wheel Loader in stock
    website:http://www.usedexcavatorstrade.com/
    Company Profile Hebei Tuolu Supply Chain Management Co. Ltd is a famous Chinese used machine trading company. It is located in Tangshan City, Hebei Province, China. We specialized in supplying used construction machinery, mainly excavators, wheel loaders and related parts. The company has many famous brands of second-hand excavators such as Caterpillar, Doosan, Hitachi, Kato, Hyundai, XCMG, Sany etc. Our company has two parking places with more than 1000 sets of excavators with different models and brands. After more than 30 years of development, our company developed from construction sites to a leading group which to do both construction works and trading for used construction machinery. With the core value of "Customer First", we try to build long term business relationship with each customer. Our Advantages are as follows: 1. More than 30 years history of used construction machinery trading; 2. Famous project contractor in Northern China; 3. Big procurement amount which can ensures variety of excavators; 4. Low price with good condition of excavators. 5. We can find the right vehicle according to buyer's request. Hebei Tuolu Supply Chain Management Co., Ltd welcomes all in China and oversea friends to build serious and long term business relationships. Our History: We are in this field for more than 30 years. At first, we just did construction works. Then we fond the great opportunity of used construction machinery, we began to cooperate with Chinese famous brands. Now we cooperate with many world famous brands and our products is not only well sold in domestic market, but also exported to Southeast Asia, such as Malaysia etc.Used Caterpillar 966H Wheel Loader in stock website:http://www.usedexcavatorstrade.com/
    WWW.USEDEXCAVATORSTRADE.COM
    China Used Caterpillar Excavator, Used Sany Excavator, Used Doosan Excavator Suppliers - TUOLU
    Hebei Tuolu Supply Chain Management Co., Ltd: Focused on used excavators' trading! Cooperation with world famous brands!
    0 Comments 0 Shares
  • UKA (Zhejiang) Intelligent Technology Co., Ltd is a high-tech enterprise specializing in R & D, production and sales of healthy seats/chairs. The company is located in Anji County, Zhejiang Province, a winner of UN Habitat Scroll of Honor Award, it is a professional manufacturer and service provider of ergonomic chairs.
    With over 30 years of professional background and development experience in chair making, the company currently focuses on the R & D and manufacturing of ergonomic chairs. The competitiveness of the company's products is attributed to our strict quality control and development ability in design. We have a province-level chair research center and a professional designer team of more than 30 people. When independently developing our own product categories, we can customize brand R & D products for customers. (we are able to offer customized products for customers.) The company always adheres to the principle that product quality is the cornerstone of enterprise development.
    The products comply with American ANSI / bifm5.1, European EN1335, EN12520, EN1728 and EN1022 testing standards, and QB / T 2280-2007 national office chair industry standards, and accredited by BV, TUV, SGS, UL and other third-party global testing agencies. The company's products are deeply favored by consumers at home and abroad. The products have been exported to North America, South America, Europe, Australia, the Middle East, Asia and other regions, and the market covers more than 60 countries and regions.
    The company always adheres to "R & D innovation and quality assurance", takes "integrating technology and art to make work and life healthier" as its mission, continues to improve the scientific development and lean manufacturing level of healthy seats/chairs, with a vision of becoming a leading provider of healthy furniture worldwide.Wholesale Mesh Office Chair with Headrest
    website:http://www.ukachair.com/
    UKA (Zhejiang) Intelligent Technology Co., Ltd is a high-tech enterprise specializing in R & D, production and sales of healthy seats/chairs. The company is located in Anji County, Zhejiang Province, a winner of UN Habitat Scroll of Honor Award, it is a professional manufacturer and service provider of ergonomic chairs. With over 30 years of professional background and development experience in chair making, the company currently focuses on the R & D and manufacturing of ergonomic chairs. The competitiveness of the company's products is attributed to our strict quality control and development ability in design. We have a province-level chair research center and a professional designer team of more than 30 people. When independently developing our own product categories, we can customize brand R & D products for customers. (we are able to offer customized products for customers.) The company always adheres to the principle that product quality is the cornerstone of enterprise development. The products comply with American ANSI / bifm5.1, European EN1335, EN12520, EN1728 and EN1022 testing standards, and QB / T 2280-2007 national office chair industry standards, and accredited by BV, TUV, SGS, UL and other third-party global testing agencies. The company's products are deeply favored by consumers at home and abroad. The products have been exported to North America, South America, Europe, Australia, the Middle East, Asia and other regions, and the market covers more than 60 countries and regions. The company always adheres to "R & D innovation and quality assurance", takes "integrating technology and art to make work and life healthier" as its mission, continues to improve the scientific development and lean manufacturing level of healthy seats/chairs, with a vision of becoming a leading provider of healthy furniture worldwide.Wholesale Mesh Office Chair with Headrest website:http://www.ukachair.com/
    WWW.UKACHAIR.COM
    China Office Chair, Ergonomic Chair, Mesh Office Chair Suppliers, Manufacturers, Factory - UKA
    UKA (Zhejiang) Intelligent Technology Co., Ltd: UKA is one of the leading all-round providers of office furniture and workplace concepts represented in European and American countries. UKA has strong ability with innovative of ergonomics, design and sustainability.
    0 Comments 0 Shares
  • MTB Vietnam provides both guided and independent Bike Tours In Vietnam. Book your road cycling or mountain biking trip today!For more at https://mtbvietnam.com/
    #Vietnambiketours #biketoursvietnam #vietnamcycling #cyclinginVietnam #biketoursnorthVietnam
    MTB Vietnam provides both guided and independent Bike Tours In Vietnam. Book your road cycling or mountain biking trip today!For more at https://mtbvietnam.com/ #Vietnambiketours #biketoursvietnam #vietnamcycling #cyclinginVietnam #biketoursnorthVietnam
    MTBVIETNAM.COM
    Home
    MTB Vietnam provides both guided and independent Bike Tours In Vietnam. Book your road cycling or mountain biking trip today!
    0 Comments 0 Shares
  • Jordan 1 Retro High White University Blue Black 555088-134

    Description: Paying tribute to Michael Jordan's college alma mater, the Air Jordan 1 Retro High OG 'University Blue' features a University of North Carolina look. Built entirely with leather, the shoe's upper appears in a mix of white and University Blue, contrasted by black on the Swoosh, collar, laces and 'Wings' logo. Perforations on the toe box provide breathability, while underfoot, the Air midsole gives way to a concentric outsole with a brighter shade of blue.TaoSneakersWe are high quality sports shoes and apparel suppliers. We sell 1:1 sneakers from our own factory. Click here https://www.taosneakers.com/h-product-detail.html?goods_id=2429 to know more details.
    Jordan 1 Retro High White University Blue Black 555088-134 Description: Paying tribute to Michael Jordan's college alma mater, the Air Jordan 1 Retro High OG 'University Blue' features a University of North Carolina look. Built entirely with leather, the shoe's upper appears in a mix of white and University Blue, contrasted by black on the Swoosh, collar, laces and 'Wings' logo. Perforations on the toe box provide breathability, while underfoot, the Air midsole gives way to a concentric outsole with a brighter shade of blue.TaoSneakersWe are high quality sports shoes and apparel suppliers. We sell 1:1 sneakers from our own factory. Click here https://www.taosneakers.com/h-product-detail.html?goods_id=2429 to know more details.
    WWW.TAOSNEAKERS.COM
    Jordan 1 Retro High White University Blue Black 555088-134
    Jordan 1 Retro High White University Blue Black 555088-134
    0 Comments 0 Shares
  • If you are thinking of sending your child to an independent (private) school or grammar school, they will more than likely have to take the 11 plus entrance exam https://northfinchleytutors.co.uk/11-plus/
    If you are thinking of sending your child to an independent (private) school or grammar school, they will more than likely have to take the 11 plus entrance exam https://northfinchleytutors.co.uk/11-plus/
    NORTHFINCHLEYTUTORS.CO.UK
    NORTH FINCHLEY TUTORS – 11 Plus
    11 Plus Tutors If you are thinking of sending your child to an independent (private) school or grammar school, they will more than likely have to take the 11
    0 Comments 0 Shares
  • The taste masking market is anticipated to grow at a steady pace till 2035, claims Roots Analysis

    Driven by the growing need to enhance palatability of oral drugs and drug adherence among pediatric and geriatric population, the demand for novel and advanced taste masking and taste assessment technologies is expected to rise in the coming years.

    London

    Roots Analysis has announced the addition of “Taste masking and Taste Assessment Services and Technologies Market, 2022-2035” report to its list of offerings.

    The inherent expertise of CMOs and CDMOs in taste masking and taste assessment of bitter drug formulations, along with capabilities to identify globally accepted tastes, develop flavor matching placebo formulations (for testing) having compliance with stringent regulatory guidelines and good clinical practices (GCPs) and proprietary technologies offering significant cost-benefits, have rendered outsourcing as a crucial aspect of taste masked formulation development and production.

    Key Market Insights

    Presently, 50 companies claim to offer taste masking and taste assessment services for oral drug formulations
    Majority (40%, each) of the service providers are based in North America and Europe, followed by companies headquartered in Asia-Pacific (18%). A large proportion (34%) of these companies are large players, followed by small (31%) and mid-sized firms (27%).

    Close to 30 technology platforms have been developed for taste masking and taste assessment of oral drug formulations
    Majority (68%) of the technology platforms are used for taste masking and taste assessment of solid oral formulations (tablets, capsules, granules and powder), followed by liquid (10%) oral formulations (suspensions, syrups and solutions).

    Partnership activity in this field has grown significantly between 2018 and 2021
    The maximum number of partnerships were established in 2021 indicating a recent rise in the interest of players engaged in the field of taste masking and taste assessment. It is worth highlighting that majority of the agreements were related to acquisition, representing 46% of the total number of partnerships signed. This is followed by agreements signed for manufacturing of oral drug formulation (13%).

    More than 460 patents have been filed / granted for taste masking and taste assessment techniques and technologies, since 2017
    Close to 60% of the patent applications have been filed by various industry and non-industry players in this domain post 2018. It is worth noting that, around 75% of the patents were filed / granted in the US, followed by European Patent Office (25%).

    North America is anticipated to capture larger share of the market by 2035
    The taste masking market is likely to be driven by technology platforms that employ coating techniques. Further, solid formulations are likely to hold greater market share.


    To request a sample copy / brochure of this report, please visit
    https://www.rootsanalysis.com/reports/taste-masking-services-market/request-sample.html


    The report features inputs from eminent industry stakeholders, who were very optimistic concerning the need of outsourcing of taste masking and taste assessment services in the coming decade. The report includes detailed transcripts of the discussions held with the following industry experts:

     Phillipe Tschopp (Head of Business Development, Glatt Pharmaceutical Services)
     David Tisi (Director of Technical Operations, Senopsys)
     Brandon Keener (Business Development Associate, Adare Pharma Solutions)

    For additional details, please visit https://www.rootsanalysis.com/reports/taste-masking-services-market.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Targeted protein degradation market, 2022-2035
    2. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.

    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com
    The taste masking market is anticipated to grow at a steady pace till 2035, claims Roots Analysis Driven by the growing need to enhance palatability of oral drugs and drug adherence among pediatric and geriatric population, the demand for novel and advanced taste masking and taste assessment technologies is expected to rise in the coming years. London Roots Analysis has announced the addition of “Taste masking and Taste Assessment Services and Technologies Market, 2022-2035” report to its list of offerings. The inherent expertise of CMOs and CDMOs in taste masking and taste assessment of bitter drug formulations, along with capabilities to identify globally accepted tastes, develop flavor matching placebo formulations (for testing) having compliance with stringent regulatory guidelines and good clinical practices (GCPs) and proprietary technologies offering significant cost-benefits, have rendered outsourcing as a crucial aspect of taste masked formulation development and production. Key Market Insights Presently, 50 companies claim to offer taste masking and taste assessment services for oral drug formulations Majority (40%, each) of the service providers are based in North America and Europe, followed by companies headquartered in Asia-Pacific (18%). A large proportion (34%) of these companies are large players, followed by small (31%) and mid-sized firms (27%). Close to 30 technology platforms have been developed for taste masking and taste assessment of oral drug formulations Majority (68%) of the technology platforms are used for taste masking and taste assessment of solid oral formulations (tablets, capsules, granules and powder), followed by liquid (10%) oral formulations (suspensions, syrups and solutions). Partnership activity in this field has grown significantly between 2018 and 2021 The maximum number of partnerships were established in 2021 indicating a recent rise in the interest of players engaged in the field of taste masking and taste assessment. It is worth highlighting that majority of the agreements were related to acquisition, representing 46% of the total number of partnerships signed. This is followed by agreements signed for manufacturing of oral drug formulation (13%). More than 460 patents have been filed / granted for taste masking and taste assessment techniques and technologies, since 2017 Close to 60% of the patent applications have been filed by various industry and non-industry players in this domain post 2018. It is worth noting that, around 75% of the patents were filed / granted in the US, followed by European Patent Office (25%). North America is anticipated to capture larger share of the market by 2035 The taste masking market is likely to be driven by technology platforms that employ coating techniques. Further, solid formulations are likely to hold greater market share. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/taste-masking-services-market/request-sample.html The report features inputs from eminent industry stakeholders, who were very optimistic concerning the need of outsourcing of taste masking and taste assessment services in the coming decade. The report includes detailed transcripts of the discussions held with the following industry experts:  Phillipe Tschopp (Head of Business Development, Glatt Pharmaceutical Services)  David Tisi (Director of Technical Operations, Senopsys)  Brandon Keener (Business Development Associate, Adare Pharma Solutions) For additional details, please visit https://www.rootsanalysis.com/reports/taste-masking-services-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com
    Request Sample - Taste Masking and Taste Assessment | Industry Analysis | Market Size | 2035
    Taste Masking and Taste Assessment Service and Technology Market report features a detailed study of the current scenario and future potential of the DNA synthesis...
    0 Comments 0 Shares
  • Manali is a town in the Indian province of Himachal Pradesh. It is arranged in the northern finish of the Kullu Valley Settled in the strong Himalayas.
    #tour,#India, #Manali
    hellovisit.in
    Manali is a town in the Indian province of Himachal Pradesh. It is arranged in the northern finish of the Kullu Valley Settled in the strong Himalayas. #tour,#India, #Manali hellovisit.in
    0 Comments 0 Shares
  • The organ-on-chip market is anticipated to grow at a CAGR of 21.3% till 2035

    In order to overcome the limitations and challenges related to animal testing, researchers and industry stakeholders are gradually adopting organ-on-chip products and technologies, which offer multiple benefits over conventional systems.

    Roots Analysis has announced the addition of “Organ-on-Chip Market, 2022-2035: Focus on Products and Technologies” report to its list of offerings.

    With the introduction of FDA Modernization Act in 2021, the use of animal models for preclinical testing is being discouraged in the pharmaceutical industry. Several players have opted to modernize their conventional testing models with organ-on-chip products and technologies. These novel products have the potential to transform the drug discovery process by simulating the human physiological and functional environment on a microfluidic system. In addition, these organ-on-chip models not only reduce the need for animal testing model but are also capable of speeding-up the research and precise evaluation of drug toxicity and cellular responses.


    To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/organ-on-a-chip-market/request-sample.html

    Key Market Insights

    Around 145 organ-on-chip products and technologies are offered by 45+ players
    Nearly 67% of the aforementioned products and technologies are commercialized; of these, 93% products and technologies are intended for drug discovery and toxicity testing related applications, followed by cancer research (44%), stem cell research (32%) and tissue engineering and regenerative medicine (21%).

    420+ patents related to organ on chip products and technologies were filed / granted, since 2017
    Based on the intellectual property distribution across the world, R&D activity related to organ on a chip technology and product is largely concentrated in China (over 30%), followed by the US (24%). The majority of the patents in this domain were filed by non-industry players (55%).

    More than 345 grants have been awarded to support the ongoing research for organ-on-chip models
    Grants worth USD 167 million have been awarded to various companies / organizations working in this domain till July 2022. Further, the number of grants awarded to stakeholders in this domain (in the US) has continuously increased between 2019 and 2021. Around 20% of the grants were funded by the National Center for Advancing Translational Sciences.

    Partnership activity in this domain has increased at a significant pace, between 2017 and 2022
    The maximum number of partnerships were established in 2020 and 2021 (21, each), indicating a recent rise in the interest of players engaged in this domain. It is worth highlighting that the majority of the deals were technology / product utilization agreements, representing around 30% of the total number of partnerships signed in the given time period.

    Amount worth over USD 680 million was invested by both private and public investors in this domain, since 2017
    Of the total amount invested, around USD 385 million was raised through grants / awards, representing around 55% of the overall funding activity in this domain. Further, 13 instances of venture capital financing were also reported, wherein players collectively raised more than USD 215 million.

    North America and Europe are anticipated to capture over 75% of the market share by 2035
    The market in Asia-Pacific and Rest of the World are anticipated to grow at a relatively faster rate to occupy overall 24% of the total market. In addition, it is worth noting that organ(s) based models are likely to capture more than 70% of the market.


    For additional details, please visit https://www.rootsanalysis.com/reports/organ-on-a-chip-market.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. 3D Cell Culture Market (4th Edition): Industry Trends and Global Forecast, 2022-2035
    2. Artificial Intelligence in Oncology Market: Industry Trends and Global Forecast, 2022-2035

    Contact:
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com


    The organ-on-chip market is anticipated to grow at a CAGR of 21.3% till 2035 In order to overcome the limitations and challenges related to animal testing, researchers and industry stakeholders are gradually adopting organ-on-chip products and technologies, which offer multiple benefits over conventional systems. Roots Analysis has announced the addition of “Organ-on-Chip Market, 2022-2035: Focus on Products and Technologies” report to its list of offerings. With the introduction of FDA Modernization Act in 2021, the use of animal models for preclinical testing is being discouraged in the pharmaceutical industry. Several players have opted to modernize their conventional testing models with organ-on-chip products and technologies. These novel products have the potential to transform the drug discovery process by simulating the human physiological and functional environment on a microfluidic system. In addition, these organ-on-chip models not only reduce the need for animal testing model but are also capable of speeding-up the research and precise evaluation of drug toxicity and cellular responses. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/organ-on-a-chip-market/request-sample.html Key Market Insights Around 145 organ-on-chip products and technologies are offered by 45+ players Nearly 67% of the aforementioned products and technologies are commercialized; of these, 93% products and technologies are intended for drug discovery and toxicity testing related applications, followed by cancer research (44%), stem cell research (32%) and tissue engineering and regenerative medicine (21%). 420+ patents related to organ on chip products and technologies were filed / granted, since 2017 Based on the intellectual property distribution across the world, R&D activity related to organ on a chip technology and product is largely concentrated in China (over 30%), followed by the US (24%). The majority of the patents in this domain were filed by non-industry players (55%). More than 345 grants have been awarded to support the ongoing research for organ-on-chip models Grants worth USD 167 million have been awarded to various companies / organizations working in this domain till July 2022. Further, the number of grants awarded to stakeholders in this domain (in the US) has continuously increased between 2019 and 2021. Around 20% of the grants were funded by the National Center for Advancing Translational Sciences. Partnership activity in this domain has increased at a significant pace, between 2017 and 2022 The maximum number of partnerships were established in 2020 and 2021 (21, each), indicating a recent rise in the interest of players engaged in this domain. It is worth highlighting that the majority of the deals were technology / product utilization agreements, representing around 30% of the total number of partnerships signed in the given time period. Amount worth over USD 680 million was invested by both private and public investors in this domain, since 2017 Of the total amount invested, around USD 385 million was raised through grants / awards, representing around 55% of the overall funding activity in this domain. Further, 13 instances of venture capital financing were also reported, wherein players collectively raised more than USD 215 million. North America and Europe are anticipated to capture over 75% of the market share by 2035 The market in Asia-Pacific and Rest of the World are anticipated to grow at a relatively faster rate to occupy overall 24% of the total market. In addition, it is worth noting that organ(s) based models are likely to capture more than 70% of the market. For additional details, please visit https://www.rootsanalysis.com/reports/organ-on-a-chip-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. 3D Cell Culture Market (4th Edition): Industry Trends and Global Forecast, 2022-2035 2. Artificial Intelligence in Oncology Market: Industry Trends and Global Forecast, 2022-2035 Contact: Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com
    Request Sample - Organ on a Chip | Market Size | Industry Analysis | 2035
    With presence of over 45 organ on a chip companies and over 420 patents in the last five years, the organ on a chip market is expected to grow at 21% CAGR till 2035
    0 Comments 0 Shares
  • Good Schools In North Bangalore
    #GoodSchoolsInNorthBangalore
    https://www.thehdfcschool.com/bengaluru/index.html
    The HDFC School Bengaluru uses a constructive approach to education. HDFC School follows a holistic CBSE curriculum focused on overall growth & development. We believe in learning through asking questions, finding solutions to problems, and the thorough application of ideas - it’s what gives our students the index edge in the real world.
    Good Schools In North Bangalore #GoodSchoolsInNorthBangalore https://www.thehdfcschool.com/bengaluru/index.html The HDFC School Bengaluru uses a constructive approach to education. HDFC School follows a holistic CBSE curriculum focused on overall growth & development. We believe in learning through asking questions, finding solutions to problems, and the thorough application of ideas - it’s what gives our students the index edge in the real world.
    0 Comments 0 Shares
  • The companion diagnostics development services market, is anticipated to grow at a CAGR of over 10%

    Given the various challenges associated with co-development of companion diagnostics and drug / therapy, drug developers prefer to rely on third-party service providers that offer customized services and advanced technologies.

    Roots Analysis has announced the addition of “Companion Diagnostics Development Services Market (2nd Edition), 2022-2035” report to its list of offerings.

    The growing pipeline of patient-centric targeted therapies has led to a surge in demand for companion diagnostics; these tests are known to improve the success rates of late-stage trials by almost three-fold. The development and approval of these FDA classified high-risk devices requires multidisciplinary expertise and an established network of R&D and production facilities that can be accessed through service providers.

    Key Market Insights

    Over 150 companies claim to offer companion diagnostics development services, globally
    Nearly 60% of the aforementioned players are based in North America, followed by the players located in Europe (30%). Further, this segment of the industry is dominated by the presence of mid-sized players (51-200 employees), which represent 40% of the total service providers.

    Nearly 15% players claim to act as one-stop shops, offering services, ranging from biomarker discovery and development to manufacturing and commercialization
    Most of the service providers (127) provide assay development services, followed by companies (124) offering services for biomarker discovery / identification. Further, NGS is the most popular technique, employed by over 100 service providers.

    Over 90 companies are actively involved in the development of companion diagnostics
    Nearly 91% of the total tests can detect mutations in a single biomarker. Amongst these, ErbB gene family (HER-2 and EGFR genes), PD-L1 genes, RAS gene family (KRAS and NRAS genes), BRCA gene family (BRCA1 and BRCA2) and BRAF emerged as the key genes which are assessed by majority of the companion diagnostics.

    Partnership activity in this domain has increased at a CAGR of ~25%, between 2017 and 2021
    Mergers and acquisitions, product development agreements and product development and commercialization agreements account for more than 60% of the total number of deals inked during the given time period. It is worth highlighting that nearly 25% of the total number of deals were signed in 2021. Further, the maximum number (177) of partnerships have been inked for companion diagnostics being developed for the treatment of oncological disorders.


    North America is expected to capture ~60% share in the companion diagnostics development services market by 2035
    Owing to the high costs associated with the clinical validation of companion diagnostics, a significant proportion (~46%) of service revenues is generated from this step, in 2035. In terms of analytical technique used, service contracts involving NGS are anticipated to contribute to more than 35% of the total service revenues generated in 2035. Further, close to 90% of the total service revenues, in 2035, are generated from companion diagnostics development projects for cancer indications.


    To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/297/request-sample.html

    One of the key objectives of the report was to estimate the existing companion diagnostics market size and the potential future growth opportunities for companion diagnostics development service providers. Based on multiple parameters, such as the service cost of various steps involved in companion diagnostics development and manufacturing, and partnerships inked in the last few years for outsourcing of such operations, we have developed informed estimates on the evolution of the market for the time period 2022- 2035.


    For additional details, please visit
    https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html or email sales@rootsanalysis.com


    You may also be interested in the following titles:
    1. Targeted protein degradation market, 2022-2035
    2. Cell Therapy Manufacturing Market, 2022-2035

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.

    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com



    The companion diagnostics development services market, is anticipated to grow at a CAGR of over 10% Given the various challenges associated with co-development of companion diagnostics and drug / therapy, drug developers prefer to rely on third-party service providers that offer customized services and advanced technologies. Roots Analysis has announced the addition of “Companion Diagnostics Development Services Market (2nd Edition), 2022-2035” report to its list of offerings. The growing pipeline of patient-centric targeted therapies has led to a surge in demand for companion diagnostics; these tests are known to improve the success rates of late-stage trials by almost three-fold. The development and approval of these FDA classified high-risk devices requires multidisciplinary expertise and an established network of R&D and production facilities that can be accessed through service providers. Key Market Insights Over 150 companies claim to offer companion diagnostics development services, globally Nearly 60% of the aforementioned players are based in North America, followed by the players located in Europe (30%). Further, this segment of the industry is dominated by the presence of mid-sized players (51-200 employees), which represent 40% of the total service providers. Nearly 15% players claim to act as one-stop shops, offering services, ranging from biomarker discovery and development to manufacturing and commercialization Most of the service providers (127) provide assay development services, followed by companies (124) offering services for biomarker discovery / identification. Further, NGS is the most popular technique, employed by over 100 service providers. Over 90 companies are actively involved in the development of companion diagnostics Nearly 91% of the total tests can detect mutations in a single biomarker. Amongst these, ErbB gene family (HER-2 and EGFR genes), PD-L1 genes, RAS gene family (KRAS and NRAS genes), BRCA gene family (BRCA1 and BRCA2) and BRAF emerged as the key genes which are assessed by majority of the companion diagnostics. Partnership activity in this domain has increased at a CAGR of ~25%, between 2017 and 2021 Mergers and acquisitions, product development agreements and product development and commercialization agreements account for more than 60% of the total number of deals inked during the given time period. It is worth highlighting that nearly 25% of the total number of deals were signed in 2021. Further, the maximum number (177) of partnerships have been inked for companion diagnostics being developed for the treatment of oncological disorders. North America is expected to capture ~60% share in the companion diagnostics development services market by 2035 Owing to the high costs associated with the clinical validation of companion diagnostics, a significant proportion (~46%) of service revenues is generated from this step, in 2035. In terms of analytical technique used, service contracts involving NGS are anticipated to contribute to more than 35% of the total service revenues generated in 2035. Further, close to 90% of the total service revenues, in 2035, are generated from companion diagnostics development projects for cancer indications. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/297/request-sample.html One of the key objectives of the report was to estimate the existing companion diagnostics market size and the potential future growth opportunities for companion diagnostics development service providers. Based on multiple parameters, such as the service cost of various steps involved in companion diagnostics development and manufacturing, and partnerships inked in the last few years for outsourcing of such operations, we have developed informed estimates on the evolution of the market for the time period 2022- 2035. For additional details, please visit https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com
    Request Sample - Companion Diagnostics Development Services Market | Industry Analysis | Market Size | 2035
    Market research report focused on companion diagnostics service providers; details include current market landscape and future growth opportunities
    0 Comments 0 Shares
More Results
Sponsored